Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.
Van Baelen K, Nguyen HL, Hamy-Petit AS, Richard F, Karsten MM, Nader Marta G, Vermeulen P, Toussaint A, Reyal F, Vincent-Salomon A, Dirix L, Dordevic AD, de Azambuja E, Larsimont D, Amato O, Maetens M, De Schepper M, Geukens T, Han SN, Baert T, Punie K, Wildiers H, Smeets A, Nevelsteen I, Floris G, Biganzoli E, Neven P, Desmedt C. Van Baelen K, et al. Among authors: de azambuja e, de schepper m. Eur J Cancer. 2023 Sep;191:112988. doi: 10.1016/j.ejca.2023.112988. Epub 2023 Jul 13. Eur J Cancer. 2023. PMID: 37573673 Free article.
Current perspectives of epothilones in breast cancer.
Cardoso F, de Azambuja E, Lago LD. Cardoso F, et al. Among authors: de azambuja e. Eur J Cancer. 2008 Feb;44(3):341-52. doi: 10.1016/j.ejca.2007.11.019. Eur J Cancer. 2008. PMID: 18178426 Review.
HER-2 as a target for breast cancer therapy.
Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. Ignatiadis M, et al. Among authors: de azambuja e. Clin Cancer Res. 2009 Mar 15;15(6):1848-52. doi: 10.1158/1078-0432.CCR-08-1844. Clin Cancer Res. 2009. PMID: 19289395 Free article. No abstract available.
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M. de Azambuja E, et al. Breast Cancer Res Treat. 2010 Jan;119(1):145-53. doi: 10.1007/s10549-009-0512-0. Breast Cancer Res Treat. 2010. PMID: 19731015 Clinical Trial.
Multifactorial approach to predicting resistance to anthracyclines.
Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C. Desmedt C, et al. Among authors: de azambuja e. J Clin Oncol. 2011 Apr 20;29(12):1578-86. doi: 10.1200/JCO.2010.31.2231. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422418 Clinical Trial.
Genomic grade adds prognostic value in invasive lobular carcinoma.
Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart M, Sotiriou C. Metzger-Filho O, et al. Among authors: de azambuja e. Ann Oncol. 2013 Feb;24(2):377-384. doi: 10.1093/annonc/mds280. Epub 2012 Oct 1. Ann Oncol. 2013. PMID: 23028037 Free article.
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart M, de Azambuja E, Loi S. Bozovic-Spasojevic I, et al. Among authors: de azambuja e. Breast. 2014 Aug;23(4):473-81. doi: 10.1016/j.breast.2014.03.012. Epub 2014 Apr 24. Breast. 2014. PMID: 24768477 Free article.
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J. Sonnenblick A, et al. Among authors: de azambuja e. Eur J Cancer. 2015 Aug;51(12):1481-9. doi: 10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11. Eur J Cancer. 2015. PMID: 26074397 Clinical Trial.
313 results